Oxford Cannabinoid Technologies
We’re pleased to announce that Oxford Cannabinoid Technologies Holdings plc will be joining us as a Bronze Sponsor of Cannabis Europa London, 2023.
Oxford Cannabinoid Technologies Holdings plc is a pharmaceutical company developing prescription cannabinoid medicines targeting the U$ multi-billion global pain market. OCTP currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain; including irritable bowel syndrome (IBS) and chemotherapy induced peripheral neuropathy (CIPN), with Phase I clinical trials, aimed at demonstrating safety and tolerability, due to commence in the near term. Trial results are expected in Q2 2023.
The global market for CIPN alone is valued at US$1.61bn and is forecast to reach US$2.37bn by the year 2027.OCTP’s drug development pipeline, comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. OCTP has a portfolio of almost 500 cannabinoid derivatives including Canopy Growth Corporation’s entire pharmaceutical cannabinoid derivative library, 14 patent families, and associated research data. OCTP is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCTP’s portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.
On becoming a Bronze Sponsor for Cannabis Europa, a spokesperson for OCT said,
“Oxford Cannabinoid Technologies is delighted to be sponsoring Cannabis Europa for the first time. The conference is undoubtedly the preeminent event and cannabis conference in Europe (arguably the world) and it’s a privilege to be involved. We look forward to meeting the other sponsors, attendees and wider community in the days ahead.”